Goserelin treatment in glandular hyperplasia.
Glandular Hyperplasia is commonly associated with meno and/or metrorrhagia. We treated 84 patients suffering from meno and/or metrorrhagia associated with simple glandular hyperplasia with a gonadotropin releasing hormone agonist, goserelin, (Zoladex, ICI Pharmaceuticals, Macclesfield. Cheshire, England), available in a depot formulation. Subcutaneous administration of goserelin 3.6 mg was repeated every 28 days for 6 months. Within the first 4 weeks from the start of therapy 45% of the patients became amenorrhoeic, within 12 weeks 100%. Only 3 patients reported continued spotting. Hysteroscopic evaluation and biopsy have shown in the 84 evaluable patients, a positive result in 76 (90.4%), demonstrating the validity of the use of this analogue in this indication. In the future it would be of value to increase the period of treatment in selected cases as well as increasing the length of the follow-up period.
Garozzo
G
G
1st Department of Obstetrics and Gynecology, University of Catania.
La Greca
M
M
Lomeo
E
E
Panella
M
M
D000328:Adult; D003692:Delayed-Action Preparations; D004714:Endometrial Hyperplasia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015907:Hysteroscopy; D007279:Injections, Subcutaneous; D008595:Menorrhagia / Q000209:etiology; D008796:Metrorrhagia / Q000209:etiology; D008875:Middle Aged; D014599:Uterus / Q000473:pathology
D003692:Delayed-Action Preparations; D017273:Goserelin